1st Quarter - Report

RIVENDELL GROUP LLP for GENENTECH

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to drug pricing. Issues related to the 340B Drug Discount Program. Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues relating to privacy and securing the data of and personal information of consumers

LobbyistCovered position, as disclosed
MATTHEW LAWRENCE BERZOK LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch
NICK KOLOVOS LA and Counsel, Rep. Anna Eshoo

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Issues related to drug pricing. Issues related to the 340B Drug Discount Program. Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease;

LobbyistCovered position, as disclosed
MATTHEW LAWRENCE BERZOK LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch
NICK KOLOVOS LA and Counsel, Rep. Anna Eshoo

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.